Noom built its brand on behavioral psychology-based weight loss through a popular consumer app, then added Noom Med in 2023 as a way for existing Noom users (and new ones) to access GLP-1 medications alongside the behavioral curriculum. The integration is structurally different from Calibrate or Found, both of which built medication-first platforms with coaching layered on top. Noom Med is the inverse — a behavioral platform with medication added as an option for patients who want it. This noom med review covers 2026 pricing, what Noom Med includes beyond the standard Noom subscription, GLP-1 access, medication safety, and how Noom Med compares to Calibrate and Found for medical weight loss. Up front, two things to keep in mind: Noom Med is a prescriber-directed, prescription-only service (not a way to “order” a specific drug on demand), and this site is not affiliated with Noom or any competitor named here — treat every price and program detail below as an estimate to verify directly.
How Noom Med fits into the Noom platform
Noom’s flagship product is the standard Noom app at $70 per month or $209 per year, offering the daily lessons, food logging, behavioral coaching content, and weekly group sessions that Noom built its reputation on. Noom Med is an add-on for patients who want medical weight loss prescribing on top of the behavioral platform — the user gets the standard Noom app experience plus access to a Noom-affiliated clinician for GLP-1 evaluation and prescribing.
The integration is meaningful because Noom’s behavioral curriculum is genuinely good. The cognitive-behavioral approach to food psychology, the daily lesson structure, and the psychology-informed coaching are differentiated from generic weight loss apps. Patients who want both medication and structured behavioral content can get them in one platform. For broader weight loss telehealth context, see our telehealth guide and best telehealth for weight loss.
Noom Med pricing in 2026
Noom Med pricing is layered, and Noom adjusts its promotional pricing frequently — so treat the figures here as directional estimates and confirm the current numbers on Noom’s own checkout before you sign up. The base Noom subscription is $70 per month. Noom Med adds approximately $149 per month for clinical access, totaling around $219 per month for the bundled program. Medications are separate. Branded Wegovy and Zepbound run at standard prices ($1,000+ monthly without insurance, lower with coverage or manufacturer savings). During the period when compounded GLP-1s were widely available, they were reported in the roughly $129–$279 monthly range through pharmacy partners — but that landscape has changed sharply (see the medication section below), so do not assume compounded pricing is still on offer.
The flexible monthly model differs from Calibrate’s longer commitment and is similar to Found’s structure. Patients can generally pause or cancel Noom Med while keeping the base Noom subscription, though cancellation terms and any minimum commitments can change — read the current terms. Insurance integration is similar to other direct-to-consumer platforms: Noom does not bill insurance for the program fee, so the membership itself is an out-of-pocket cost, and medication insurance handling is patient-driven. Importantly, the Noom Med membership is a service fee, not health insurance — it does not count toward a deductible or out-of-pocket maximum.
What Noom Med includes
The Noom Med tier adds clinician evaluation for GLP-1 eligibility, ongoing monthly clinician check-ins via the app, prescription management, asynchronous messaging with the prescriber, and access to Noom’s pharmacy partner network. Patients also retain full access to the standard Noom features: daily lessons, food logging with the company’s calorie-density system, behavioral coaching, group sessions, and progress tracking.
The integration of behavioral content with medical care is the platform’s primary value proposition. A patient logging food in Noom can see their patterns alongside their GLP-1 dose schedule, with both pieces of data visible to the Noom Med clinician. Compared to using a separate GLP-1 platform alongside an unaffiliated weight loss app, this integration produces a more cohesive experience. It bears repeating, though, that the prescribing decision sits with the clinician: eligibility screening, the choice of medication, and any dose changes are directed by the prescriber based on your history, not selected from a menu by the patient.
Which GLP-1 medications Noom Med prescribes
Noom Med’s formulary centers on FDA-approved GLP-1 and GIP/GLP-1 receptor agonist medications for weight management — principally semaglutide (marketed as Wegovy for weight loss and Ozempic for type 2 diabetes) and tirzepatide (marketed as Zepbound for weight loss and Mounjaro for diabetes). Prescribing follows FDA labeling for eligibility, generally a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, high cholesterol, or type 2 diabetes.
The compounded GLP-1 picture is the single biggest thing that has changed since this program launched. Compounding pharmacies were permitted to prepare semaglutide and tirzepatide on a large scale primarily because the FDA listed those drugs in shortage. The FDA subsequently declared the tirzepatide and semaglutide shortages resolved, and the enforcement grace periods that had allowed widespread compounding wound down in 2025. As a practical result, broad “compounded GLP-1” access through telehealth platforms has narrowed substantially, and where any compounding continues it is generally limited to legitimate clinical exceptions (for example, a documented medical need for a formulation that differs from the commercial product). If a program advertises cheap compounded GLP-1s, treat that as something to verify carefully and ask exactly what is being dispensed and under what authority. Confirm Noom Med’s current offerings directly, because they may differ from what was available in prior years.
GLP-1 safety: what every patient should know
GLP-1 medications are effective but not casual drugs, and any honest review has to flag the safety profile. According to MedlinePlus, semaglutide carries a boxed warning — the FDA’s most serious — because it caused thyroid C-cell tumors, including medullary thyroid carcinoma, in rodent studies; the human risk is not established, but the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide carries a comparable class warning. Patients are told to seek care for a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.
Common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and more serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and vision changes in some patients. This is exactly why the medication is prescriber-directed: dosing starts low and is titrated upward on a schedule the clinician sets, and self-adjusting the dose or sourcing the drug outside a legitimate prescription is unsafe. This article does not provide dosing instructions; those come from your prescriber. For general context on healthy weight and behavior change, the CDC maintains plain-language resources.
Noom Med’s clinical depth
The clinical infrastructure is reasonable but not exceptional. Noom Med uses board-certified physicians and nurse practitioners, follows current FDA labeling for GLP-1 eligibility, and screens for contraindications such as the thyroid-tumor history noted above. The intake assessment is competent but generally less comprehensive than Found’s metabolic-health-focused intake or Calibrate’s more structured program.
The medication formulary is narrower than Found’s. Noom Med primarily prescribes GLP-1 medications rather than the broader formulary of older weight loss medications that Found offers. Patients with insulin resistance who might do well on metformin, or those with comorbid depression who might benefit from bupropion, could get a less customized medication match through Noom Med than through Found — though, again, any such choice is the clinician’s to make. For comparison, see our Found vs Noom head-to-head.
The standard Noom app’s role
The standard Noom app’s behavioral content is genuinely the platform’s strongest asset. The cognitive-behavioral framing of food psychology, the calorie-density-based “green/yellow/red” food categorization, and the daily lesson structure produce real behavioral engagement for many users.
For patients who’d benefit from behavioral support alongside GLP-1 medication, this content is more substantive than the in-app content offered by Hims or Ro weight loss programs. Whether this content is worth the price premium over alternatives depends on whether the patient actually engages with it — Noom’s free-trial-to-paid conversion produces high abandonment rates, and many users pay for months without using the app meaningfully. Behavioral support also matters after GLP-1 therapy: because much of the weight lost on these drugs can return when they are stopped, the habit-change scaffolding is arguably most valuable for maintenance, not just the active medication phase.
Where Noom Med falls short
The pricing stacking is awkward. At $219+ per month for the bundle plus medication costs, Noom Med is not dramatically cheaper than alternatives, and patients who’d benefit primarily from medication access are paying for the behavioral content whether they use it or not.
The clinical depth is mid-tier. For patients with complex metabolic profiles, Found’s broader assessment and formulary may produce better-matched medication choices. For patients who want intensive coaching, Calibrate’s structured sessions move outcomes more than Noom’s app-based content for many users. Noom Med occupies a middle position that fits patients comfortable with app-based behavioral content who want medication added on top, but doesn’t excel in any single dimension. The narrowing of compounded GLP-1 access also removes what had been a lower-cost on-ramp for some patients, pushing more people toward branded pricing.
Noom Med vs Calibrate, Found, Hims, and Ro
Compared to Calibrate, Noom Med has lighter clinical engagement and lighter coaching but a more flexible subscription. Calibrate’s intensive program fits patients who want and use coaching; Noom Med fits patients comfortable with app-based behavioral content. Compared to Found, Noom Med has stronger behavioral content while Found has broader medication options and stronger clinical assessment. See Noom vs Calibrate and Found vs Noom for the detailed head-to-heads.
Compared to Hims and Ro weight loss programs, Noom Med has substantially more behavioral content but less aggressive medication marketing. Hims and Ro often deliver medication access at lower total program cost; Noom Med delivers integrated behavioral support at a price premium. Across all of these, the underlying branded medications are the same FDA-approved products at broadly similar list prices — the differences are in the coaching, the clinical intake, and the membership fee, not in the drug itself.
Frequently Asked Questions
Is Noom Med separate from regular Noom?
Noom Med is an add-on tier to the standard Noom subscription. Most users who want Noom Med subscribe to both, with the bundle pricing reflecting the combined service. Confirm the current structure and price at signup, as Noom changes its packaging periodically.
Does Noom Med prescribe Ozempic?
Noom Med primarily prescribes FDA-approved weight-loss medications including Wegovy (semaglutide) and Zepbound (tirzepatide). Ozempic and Mounjaro are FDA-approved for type 2 diabetes specifically, so any use for weight loss would be off-label and is a decision for the prescriber based on your medical history.
Can I still get compounded GLP-1s through Noom Med?
Widespread compounded GLP-1 access has wound down since the FDA declared the semaglutide and tirzepatide shortages resolved and the compounding enforcement grace periods ended in 2025. Current availability is limited and program-specific — verify directly with Noom Med what it dispenses today and under what authority before assuming compounded options are available.
Does Noom Med take insurance?
Noom Med does not bill insurance for the program fee, so the membership is an out-of-pocket cost and is not itself insurance. The platform coordinates GLP-1 prescriptions where insurance can apply to the medication itself. Verify your plan’s GLP-1 coverage independently, since many plans restrict or exclude weight-loss drugs.
Can I use Noom Med without the regular Noom app?
Generally no — Noom Med is structured as an add-on to the base Noom subscription. The integration of behavioral content and clinical care is the platform’s primary value proposition, and the standard Noom features are a core part of the experience.
How does Noom Med compare to Calibrate?
Noom Med leverages Noom’s stronger behavioral content but has lighter clinical engagement than Calibrate. Calibrate’s structured program with regular coaching produces stronger outcomes for patients who engage; Noom Med’s flexible subscription is better for patients who want app-based behavioral support without a longer upfront commitment.
The bottom line on Noom Med
Noom Med is a reasonable choice for patients already engaged with the Noom app who want to add medication under clinician supervision. The integration of behavioral content with clinical care is genuine, and the cognitive-behavioral framing fits some patients well. For patients who haven’t already adopted the Noom app, the bundle is more expensive than alternatives without dramatically better outcomes. For comprehensive medical weight loss with intensive coaching, Calibrate is structurally stronger. For broad medication options with lighter coaching, Found is more flexible. For pure GLP-1 access at lower cost, Hims or Ro deliver more efficiently. Noom Med fits the niche where behavioral content matters but the patient also wants medication — just go in knowing the prices are moving targets, compounded options have narrowed, and the medication itself is a serious drug best managed by a clinician who knows your history.
TL;DR & disclaimer: Noom Med is a prescriber-directed, prescription-only GLP-1 add-on to Noom’s behavioral app — not standalone medication delivery and not insurance. Bundled pricing runs roughly $219/month (about $70 base Noom + $149 clinical access) with medication billed separately; all figures are estimates to verify directly with Noom. Noom Med mainly prescribes brand GLP-1s (semaglutide/tirzepatide); broad compounded access has wound down since the FDA-declared shortages resolved and grace periods ended in 2025 — confirm current offerings. GLP-1s carry a class boxed warning about thyroid C-cell tumors and are contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2; eligibility and dosing are set by the prescriber, never self-directed. This is general information, not medical advice, and this site is not affiliated with Noom or the other programs named.
Sources
- MedlinePlus — “Semaglutide Injection” (medlineplus.gov): thyroid boxed warning, MEN 2 contraindication, side effects, and prescriber-directed dosing
- U.S. Food & Drug Administration — GLP-1 labeling and compounding/drug-shortage guidance (fda.gov)
- Noom / Noom Med program and pricing pages (noom.com) — offerings and pricing are as advertised and should be verified directly
- CDC — Healthy Weight and behavioral health resources (cdc.gov)